Prognostic Significance of Epidermal Growth Factor Receptor in Glioblastoma Patients
Speaker Credentials
BS
College
College of Allopathic Medicine
Format
Poster
Start Date
6-11-2020 10:15 AM
End Date
6-11-2020 10:30 AM
Abstract
Prognostic Significance of Epidermal Growth Factor Receptor in Glioblastoma Patients Vikram Patel, MS-2, Dr. Kiran C. Patel College of Allopathic Medicine, Davie, FL; Waseem Wahood, MS-2, Dr. Kiran C. Patel College of Allopathic Medicine, Davie, FL; Rahul Kumar, HSD, Department of Neurological Surgery, University of Miami, Miami, FL; Tatiana Slepak, MS, Department of Neurological Surgery, University of Miami, Miami, FL; Daniel Eichberg, MD, Department of Neurological Surgery, University of Miami, Miami, FL; Michael Ivan, MD, Department of Neurological Surgery, University of Miami, Miami, FL Objective - This study aims to come to a conclusion on the prognostic capabilities of Epidermal Growth Factor Receptor (EGFR) amplification in glioblastoma patients through a meta-analysis. Background - Glioblastoma multiforme (GBM) is a grade IV brain tumor of astrocytic origin that accounts for more than 60% of all brain tumors in adults. Patients with GBM often face a poor prognosis with median survival times being 14 to 15 months. A frequent genetic alteration seen in approximately 40% of GBM cases is the amplification of Epidermal growth factor receptor (EGFR). EGFR is part of a family of tyrosine kinase receptors that have been shown to be important in cell growth and proliferation. Methods - A literature search was conducted on PubMed until July 10, 2020. The records were sorted based on our inclusion and exclusion criteria. 980 publications were screened of which 17 publications, containing 1976 patients, were included. 9 of the 17 studies contained individual patient data through which hazards ratio (HR) could be derived and the rest reported HRs. A meta-analysis was conducted of the HRs. Results - EGFR amplification was not found to be associated with a difference in the prognosis of GBM patients (HR = .92, 95% CI .82-1.03, P=.454). Conclusion - This meta-analysis indicates that EGFR amplification is not an independent prognostic factor in GBM patients. Grant - None
Prognostic Significance of Epidermal Growth Factor Receptor in Glioblastoma Patients
Prognostic Significance of Epidermal Growth Factor Receptor in Glioblastoma Patients Vikram Patel, MS-2, Dr. Kiran C. Patel College of Allopathic Medicine, Davie, FL; Waseem Wahood, MS-2, Dr. Kiran C. Patel College of Allopathic Medicine, Davie, FL; Rahul Kumar, HSD, Department of Neurological Surgery, University of Miami, Miami, FL; Tatiana Slepak, MS, Department of Neurological Surgery, University of Miami, Miami, FL; Daniel Eichberg, MD, Department of Neurological Surgery, University of Miami, Miami, FL; Michael Ivan, MD, Department of Neurological Surgery, University of Miami, Miami, FL Objective - This study aims to come to a conclusion on the prognostic capabilities of Epidermal Growth Factor Receptor (EGFR) amplification in glioblastoma patients through a meta-analysis. Background - Glioblastoma multiforme (GBM) is a grade IV brain tumor of astrocytic origin that accounts for more than 60% of all brain tumors in adults. Patients with GBM often face a poor prognosis with median survival times being 14 to 15 months. A frequent genetic alteration seen in approximately 40% of GBM cases is the amplification of Epidermal growth factor receptor (EGFR). EGFR is part of a family of tyrosine kinase receptors that have been shown to be important in cell growth and proliferation. Methods - A literature search was conducted on PubMed until July 10, 2020. The records were sorted based on our inclusion and exclusion criteria. 980 publications were screened of which 17 publications, containing 1976 patients, were included. 9 of the 17 studies contained individual patient data through which hazards ratio (HR) could be derived and the rest reported HRs. A meta-analysis was conducted of the HRs. Results - EGFR amplification was not found to be associated with a difference in the prognosis of GBM patients (HR = .92, 95% CI .82-1.03, P=.454). Conclusion - This meta-analysis indicates that EGFR amplification is not an independent prognostic factor in GBM patients. Grant - None